Benzodiazepine Withdrawal Symptoms

This page covers the symptoms, the timeline by drug type, withdrawal while still taking the drug, protracted withdrawal, the emergency signs and how a supervised taper is structured.

Key Takeaways

• Benzodiazepine withdrawal produces seizures and delirium at its severe end, and the 2025 Joint Clinical Practice Guideline on Benzodiazepine Tapering describes both as life-threatening.
• Rebound anxiety and insomnia usually begin within 1 to 4 days of stopping, depending on the drug's half-life, and the full withdrawal syndrome usually lasts 10 to 14 days.
• Benzodiazepine withdrawal can start before the last dose, either between doses of a short-acting drug or during a gradual dose reduction.
• Protracted benzodiazepine withdrawal describes symptoms lasting beyond roughly 4 to 6 weeks, and some people experience them for months or years.
• The FDA names seizures, catatonia, delirium tremens, hallucinations, mania and psychosis among the severe withdrawal symptoms that need a clinician.

What are the symptoms of benzo withdrawal?

Benzo withdrawal symptoms range from anxiety, poor sleep and irritability to tremor, sweating, a pounding heart, nausea and muscle pain. At the severe end, benzodiazepine withdrawal produces seizures, delirium (sudden, severe confusion) and psychosis (losing touch with reality), which need emergency medical care.

Pétursson's 1994 review in the journal Addiction described the classic benzodiazepine withdrawal syndrome. That syndrome typically includes sleep disturbance, irritability, tension, anxiety, panic attacks, hand tremor, sweating, poor concentration, nausea, headache, palpitations and muscle stiffness. Pétursson also reported seizures and psychotic reactions in people withdrawing from high doses.

8 body systems the 2025 guideline uses to group benzodiazepine withdrawal symptoms:

• General symptoms: raised blood pressure, headaches, sweating and night sweats
• Mood symptoms: anxiety, panic attacks, low mood, irritability and agitation
• Heart symptoms: chest pain, palpitations and a fast heart rate
• Stomach and gut symptoms: abdominal cramps, diarrhea, nausea and vomiting
• Brain and nerve symptoms: poor memory, confusion, delirium, seizures, sensitivity to light and sound, tingling and ringing in the ears
• Muscle symptoms: muscle pain, twitches, tremors and balance problems
• Neuropsychiatric symptoms: restlessness, feeling detached or unreal (depersonalization and derealization), paranoia, and suicidal thoughts
• Sleep symptoms: insomnia, nightmares, or sleeping too much

The stomach and gut group covers what many people online call "benzo belly." The guideline places cramps, nausea and diarrhea in the gastrointestinal group of withdrawal symptoms.

Rebound symptoms and withdrawal symptoms overlap. Herman and colleagues defined rebound as the original symptoms returning worse than before, such as the anxiety a benzodiazepine was first prescribed for. The 2025 guideline states that telling rebound apart from withdrawal is often difficult.

The timing of each symptom depends on the benzodiazepine's half-life, which sets the benzodiazepine withdrawal timeline.

What is the benzodiazepine withdrawal timeline?

The benzodiazepine withdrawal timeline follows the drug's half-life, meaning how long the body takes to clear half a dose. Rebound anxiety and insomnia usually start within 1 to 4 days of stopping, and the full withdrawal syndrome usually lasts 10 to 14 days.

3 withdrawal patterns Pétursson described after stopping a normal dose:

• Rebound anxiety and insomnia, the most common pattern, beginning within 1 to 4 days depending on the drug's half-life
• The full withdrawal syndrome, usually lasting 10 to 14 days
• A return of the original anxiety, which persists until the anxiety itself is treated

The 2025 guideline asks clinicians to watch for post-acute withdrawal symptoms for 2 to 4 weeks after the final dose. Symptoms lasting beyond roughly 4 to 6 weeks are classed as protracted withdrawal.

No single peak day applies to every benzodiazepine, because onset moves with each drug's half-life.

Alcohol and benzodiazepines both act on GABA, the brain's main calming chemical, and Santos and Olmedo class both drugs as sedative-hypnotics (calming and sleep-inducing drugs). That shared drug class makes the alcohol withdrawal timeline a direct comparison for the benzodiazepine withdrawal timeline.

Can withdrawal start while someone is still taking a benzodiazepine?

Yes. Benzodiazepine withdrawal can start before the last pill in two ways: between doses of a short-acting drug, called interdose withdrawal, and during a dose reduction, even a gradual one.

Interdose withdrawal means withdrawal symptoms that surface as the level of a short-acting benzodiazepine falls before the next dose is due. People describe this as feeling shaky, jumpy or anxious between doses.

Herman, Brotman and Rosenbaum reported in 1987 on 48 people with panic disorder who had rebound symptoms on alprazolam and switched to clonazepam, a longer-acting drug. Of those 48 patients, 39 (82%) rated clonazepam better, citing less frequent dosing and no interdose anxiety.

Withdrawal during a taper is the second route. The FDA states that even a gradual dose decrease can produce withdrawal symptoms, including anxiety, insomnia, irritability, tremors, panic attacks, blurred vision, memory problems and muscle pain. Santos and Olmedo likewise name a dose reduction, not only a full stop, as a trigger for sedative-hypnotic withdrawal.

Heather Ashton wrote in 1991 that many benzodiazepine withdrawal symptoms result from tolerance to the drug. Tolerance means the brain has adjusted to the benzodiazepine, so a lower drug level now registers as a shortfall.

A specific set of withdrawal signs moves benzodiazepine withdrawal from uncomfortable to a medical emergency.

What are the emergency signs of benzodiazepine withdrawal?

The emergency signs of benzodiazepine withdrawal are seizures, delirium, hallucinations, catatonia (being unable to speak or move normally), psychosis and thoughts of harming oneself or someone else. The 2025 guideline describes seizures and delirium as life-threatening.

Benzodiazepine withdrawal belongs to the sedative-hypnotic withdrawal syndromes, which can be life-threatening. Santos and Olmedo place benzodiazepines in that group alongside alcohol, barbiturates, GHB and baclofen, all of which act on GABA.

8 severe withdrawal symptoms the FDA tells patients to report to a clinician:

• Seizures
• Catatonia, meaning an inability to speak, a rigid body, or repeated meaningless movements
• Delirium tremens, meaning shaking, shivering, an irregular heartbeat and sweating
• Hallucinations, meaning seeing or hearing things that others do not
• Psychosis, meaning false beliefs
• Mania, meaning extreme high mood, delusions and overactivity
• Depression
• Thoughts about killing oneself or someone else

Thoughts of suicide during benzodiazepine withdrawal are an emergency. The 988 Suicide and Crisis Lifeline answers calls, texts and chats 24 hours a day.

5 factors the 2025 guideline links to more severe benzodiazepine withdrawal:

• A shorter half-life with fewer active metabolites, as with alprazolam
• Daily benzodiazepine use
• A higher total daily benzodiazepine dose
• A longer duration of benzodiazepine use
• A history of severe benzodiazepine withdrawal

Emergency signs belong to the acute phase, while a separate set of lingering symptoms defines protracted benzodiazepine withdrawal.

What is protracted benzodiazepine withdrawal?

Protracted benzodiazepine withdrawal is a set of symptoms that persist after the drug should have cleared the body, beyond roughly 4 to 6 weeks. The 2025 guideline states that some people experience protracted withdrawal symptoms for months or years.

Heather Ashton described in 1991 how first-week withdrawal symptoms tend to merge with more persistent symptoms that may last for many months. Ashton listed anxiety and a variety of sensory and motor symptoms among those persistent symptoms.

4 groups of protracted withdrawal symptoms in the 2025 guideline:

• Psychological symptoms: anxiety, depression, agitation, loss of pleasure (anhedonia) and hallucinations
• Neurological symptoms: poor memory, distractedness, crawling skin sensations, pins and needles, and ringing in the ears
• Neuropsychiatric symptoms: inner restlessness (akathisia) and psychosis
• Other symptoms: movement problems, stomach problems, insomnia and dizziness

People in protracted withdrawal often describe "windows and waves," meaning stretches of relief broken by returns of symptoms. The FDA reported in 2020 that some patients experienced withdrawal symptoms lasting many months.

The 2025 guideline reports that the term benzodiazepine-induced neurological dysfunction (BIND) has been proposed for lasting nerve and brain problems that may emerge from benzodiazepine use. The 2025 guideline states that the brain mechanisms behind protracted withdrawal are not well established and need further research.

Tracking benzodiazepine withdrawal across both phases depends on structured clinical measurement.

How do clinicians measure benzodiazepine withdrawal?

Clinicians measure benzodiazepine withdrawal by tracking vital signs, such as pulse and blood pressure, alongside the symptoms the patient reports. The 2025 guideline names these two as the most important items to monitor during withdrawal.

One named tool is the Clinical Institute Withdrawal Assessment for Benzodiazepines (CIWA-B), published by Busto, Sykora and Sellers in 1989. Busto's team built the CIWA-B from 23 high-dose patients and 40 long-term prescribed users.

The 2025 guideline found little to no evidence of validation for the CIWA-B or for the Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ). Both scales were developed with small patient groups, so clinicians do not use them frequently in practice.

Structured symptom records still help, according to the guideline, because they improve the objectivity and consistency of symptom measurement. Those measurements guide the pace of a supervised benzodiazepine taper.

How is a medically supervised benzodiazepine taper structured?

A medically supervised benzodiazepine taper lowers the dose in small, spaced steps set with the patient, slows or pauses when symptoms become significant, and continues follow-up after the last dose. The 2025 guideline states that tapering can typically be managed in outpatient settings.

5 stages in the taper structure the 2025 guideline describes:

• Consolidation, converting several benzodiazepines into an equivalent dose of one
• An optional switch from a short-acting drug such as alprazolam to a longer-acting one
• Gradual benzodiazepine dose reductions, planned jointly by the clinician and the patient
• Smaller dose steps or a pause in the taper when withdrawal symptoms become significant
• Follow-up for post-acute withdrawal symptoms for 2 to 4 weeks after the final dose

The guideline flags the final stretch, stating that tapering can become more difficult as patients approach the point of stopping. Severe or complicated withdrawal belongs in an inpatient or residential medically managed setting, with vital signs, structured assessment tools and a seizure-risk assessment.

The 2025 guideline addresses tapering for patients whose risks from benzodiazepines now outweigh the benefits.

Medicines that ease benzodiazepine withdrawal remain unproven. A 2018 Cochrane review by Baandrup and colleagues included 38 trials and could draw no firm conclusions about any drug for benzodiazepine discontinuation.

Pregabalin showed a possible reduction in withdrawal symptoms in one trial of 106 people, on very low-quality evidence. One flumazenil trial was stopped because of severe panic reactions. The 2025 guideline advises against flumazenil for tapering because flumazenil risks seizures that resist treatment.

The guideline allows phenobarbital, a very long-acting barbiturate, to be considered for inpatient withdrawal management on low-certainty evidence. Where withdrawal risk is too high for outpatient care, the next step is a medically monitored withdrawal management program.

Frequently asked questions

Sources

1. Brunner, E. et al., for the American Society of Addiction Medicine and nine partner societies (2025). Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits, Journal of General Internal Medicine, 40(12), 2814-2859. Seizure and delirium risk, withdrawal during gradual reduction, symptom groups, severity factors, protracted withdrawal, CIWA-B validation, taper structure and adjunct status.
2. US Food and Drug Administration (2020). FDA Drug Safety Communication: FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class. Life-threatening seizures on abrupt or rapid reduction, symptoms during a gradual decrease, and the list of severe withdrawal symptoms.
3. Pétursson, H. (1994). The benzodiazepine withdrawal syndrome, Addiction, 89(11), 1455-1459. The classic symptom list and the three withdrawal patterns, including onset within 1 to 4 days and a full syndrome of 10 to 14 days.
4. Busto, U. E., Sykora, K. and Sellers, E. M. (1989). A clinical scale to assess benzodiazepine withdrawal, Journal of Clinical Psychopharmacology, 9(6), 412-416. Origin and development sample of the CIWA-B.
5. Ashton, H. (1991). Protracted withdrawal syndromes from benzodiazepines, Journal of Substance Abuse Treatment, 8(1-2), 19-28. Tolerance as a source of withdrawal symptoms and first-week symptoms merging into months-long symptoms.
6. Herman, J. B., Brotman, A. W. and Rosenbaum, J. F. (1987). Rebound anxiety in panic disorder patients treated with shorter-acting benzodiazepines, Journal of Clinical Psychiatry, 48(Suppl), 22-28. Definition of rebound and the interdose anxiety finding in 48 patients switched to clonazepam.
7. Santos, C. and Olmedo, R. E. (2017). Sedative-Hypnotic Drug Withdrawal Syndrome: Recognition and Treatment, Emergency Medicine Practice, 19(3), 1-20. Benzodiazepines among the GABA-acting sedative-hypnotics whose withdrawal, after a stop or a dose reduction, can be life-threatening.
8. Baandrup, L. et al. (2018). Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users, Cochrane Database of Systematic Reviews, 3, CD011481. Status of pregabalin, flumazenil and other adjuncts, with no firm conclusions possible.